Skip to main content
Premium Trial:

Request an Annual Quote

Vermillion Distributes Shares to Board, CSO

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Vermillion said last week that it has distributed shares to certain board members and its chief scientific officer pursuant to its debtor incentive plan.

Board members James Burns and John Hamilton each received 35,295 shares of the company's stock pursuant to the incentive plan, which was approved by the US Bankruptcy Court in Delaware in April as part of the company's plan to emerge from Chapter 11 protection. Vermillion emerged from Chapter 11 protection earlier this year.

Burns and Hamilton were each granted 60,508 shares of common stock under the incentive plan, subject to a 24-month vesting schedule that began on June 22, 2009.The remaining 25,213 shares granted to Burns and Hamilton each will vest monthly over the next 10 months, the company said.

Also Vermillion, now based in Austin, Texas, said that its board has approved the granting of 20,169 restricted shares of its common stock to CSO Eric Fung. The shares are subject to a 24-month vesting schedule that began on June 22, 2009, and 11,765 of those shares are vested and have been distributed to Fung. The remaining 8,404 shares will vest over the next 10 months.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.